Loading...
01/11 16:18
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong revenue growth, significant reductions in operating expenses, and promising developments in castor seed sales and field trials. The Q&A section reveals optimism about future collaborations and advancements, particularly in the ChemPass AI platform. Despite some vague responses, the focus on new strategies and partnerships suggests a positive outlook. The financial improvements and strategic plans indicate a likely stock price increase of 2% to 8% over the next two weeks.
Total Revenues (First Half 2025) $3.2 million, an increase of $0.9 million (39%) year-over-year. This increase was primarily driven by strong seed sales from the subsidiary, Casterra.
Research and Development Expenses (First Half 2025) $4.8 million, a decrease of $1.7 million (26%) year-over-year. This decrease is primarily due to reduced R&D activities at Biomica and the discontinuation of operations at Canonic.
Sales and Marketing Expenses (First Half 2025) $800,000, a decrease of $300,000 (27%) year-over-year. The reduction reflects lower headcount across several subsidiaries.
Total Operating Expenses (First Half 2025) $7.7 million, a decrease of $3.4 million (31%) year-over-year. This significant decrease is mainly attributed to the reduced level of activity in subsidiaries.
Cash and Short-Term Bank Deposits (End of First Half 2025) $11.7 million. This does not include expected proceeds from the sales of Lavie Bio's assets and MicroBoost AI for Ag.
Revenues (Second Quarter 2025) $0.9 million, an increase of $0.3 million (50%) year-over-year. This increase was primarily driven by higher revenues recognized by Casterra attributed to seed sales.
Operating Loss (First Half 2025) $6.1 million, a decrease of $3.3 million (35%) year-over-year. This decrease is mainly due to decreased operating expenses.
Net Loss (First Half 2025) $7.7 million, a decrease of $2.1 million (21%) year-over-year. This decrease was primarily due to decreased operating expenses and increased financing income, partially offset by increased loss from operations held for sale and reduced revenues.
ChemPass AI: Evogene has completed version 1 of its generative AI foundation model for small molecule design in collaboration with Google Cloud. This model enhances ChemPass AI's capabilities in identifying novel molecules for pharma and agriculture.
Casterra: Casterra has entered new markets and marketing channels, showing strong potential for sustainable revenue growth.
Cost Reduction: Evogene executed a cost reduction plan, reducing R&D expenses by $1.7 million and sales/marketing expenses by $0.3 million in the first half of 2025. Workforce reductions included 40% at AgPlenus and 30% at Evogene.
Cash Flow Enhancement: Evogene sold Lavie Bio's activities and MicroBoost AI for Ag to ICL for $18.75 million, significantly improving cash flow.
Strategic Shift: Evogene is focusing on its ChemPass AI platform for small molecule innovation in pharma and agriculture. It integrated AgPlenus into Evogene and reduced activities in Biomica and Lavie Bio.
Pharma Collaboration: Evogene partnered with Tel Aviv University to develop small molecule therapeutics targeting diseases caused by metabolite accumulation.
Geopolitical Risks: The ongoing war between Israel, Hamas, and Hezbollah, as well as potential escalations in Israel's northern border, poses significant risks to the company's operations and overall stability.
Strategic Execution Risks: The company is undergoing a strategic shift, including the sale of major assets and restructuring efforts, which involve significant workforce reductions (30% at Evogene, 40% at AgPlenus). These changes could disrupt operations and delay strategic goals.
Financial Risks: Despite cost reductions and asset sales, the company has a limited operational runway of approximately 18 months, raising concerns about long-term financial sustainability.
Subsidiary Performance Risks: Several subsidiaries, including Biomica and Lavie Bio, are scaling back operations or focusing on limited activities, which could impact revenue streams and strategic objectives.
Market and Revenue Risks: Revenue growth is primarily driven by seed sales from Casterra, but other subsidiaries like AgPlenus have seen revenue declines, particularly from reduced licensing agreements.
Operational Risks: The company is heavily reliant on its ChemPass AI platform for future growth, and any delays or failures in its development or commercialization could significantly impact its strategic objectives.
ChemPass AI Platform: Evogene is focusing on its ChemPass AI platform for accelerating small molecule-based innovation in pharma and agriculture. The platform will serve two key verticals: pharma for small molecule therapeutics and agriculture for crop protection products. The company plans to continue advancing the platform's technology, including partnerships with global tech leaders like Google.
Pharma Vertical: Evogene is establishing a partner ecosystem in pharma, including academic and industry collaborations in Israel and internationally. A dedicated business development arm will be created to accelerate growth in this vertical.
Agriculture Vertical: AgPlenus will continue strategic collaborations with Bayer and Corteva, with expectations for further growth and new partnerships later in 2025.
Subsidiary Focus: Lavie Bio will maintain its existing collaboration agreement and distribute funds to shareholders. Biomica will focus on completing its clinical trial by early 2026 and securing partners for development programs. Casterra will continue operations, entering new markets and marketing channels to build a sustainable revenue stream.
Financial Position: Evogene has a solid financial foundation with an operational runway of approximately 18 months. The company raised $4.4 million in June 2025 and completed a transaction with ICL, generating $15.25 million from Lavie Bio's activity sale and $3.5 million from MicroBoost AI for Ag.
Cost Reduction: The company implemented significant cost reductions, including a 30% workforce reduction at Evogene and a 40% reduction at AgPlenus. These changes are expected to reflect in financial reports starting Q3 2025.
Revenue Growth: Casterra's seed sales drove revenue growth in the first half of 2025. The company anticipates continued revenue growth through new market entries and business initiatives.
Clinical Trial Completion: Biomica is expected to complete its clinical trial by early 2026.
The selected topic was not discussed during the call.
The earnings call reveals a mixed but overall positive sentiment. Financial performance shows improvement in net loss and operating loss, though revenues slightly decreased. The AI ChemPass platform is gaining interest, with potential partnerships on the horizon. Management's enthusiasm for AI ChemPass and planned IR activities could boost investor confidence. Despite some unclear responses in the Q&A, the focus on strategic partnerships and financial health supports a positive outlook for stock price movement.
The earnings call highlights strong revenue growth, significant reductions in operating expenses, and promising developments in castor seed sales and field trials. The Q&A section reveals optimism about future collaborations and advancements, particularly in the ChemPass AI platform. Despite some vague responses, the focus on new strategies and partnerships suggests a positive outlook. The financial improvements and strategic plans indicate a likely stock price increase of 2% to 8% over the next two weeks.
The earnings call presents a mixed picture. While there are positive developments, such as the acquisition of Lavie Bio by ICL and reduced expenses, there are concerns over declining revenues, operational risks, and funding challenges. The Q&A session highlights management's reluctance to provide clear guidance, raising uncertainties. Despite reduced expenses and a cash inflow from asset sales, the reliance on subsidiaries for revenue and the lack of clarity on future orders temper optimism. Given these factors, the stock price is likely to remain stable, resulting in a neutral sentiment.
The earnings call reveals several concerning factors: a significant decline in revenue, a reduced cash position, and geopolitical risks. Despite some positive developments like the acquisition of Lavie Bio and reduced expenses, the dependency on collaborations and the absence of license fee payments pose substantial risks. Additionally, the financial sustainability is questionable due to decreased cash reserves and reliance on future funding. The analysts' sentiment is unclear, but the overall financial picture and risks suggest a negative market reaction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
